These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 26526752)

  • 1. A river model to map convergent cancer evolution and guide therapy in RCC.
    Wei EY; Hsieh JJ
    Nat Rev Urol; 2015 Dec; 12(12):706-12. PubMed ID: 26526752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcome tumor heterogeneity-imposed therapeutic barriers through convergent genomic biomarker discovery: A braided cancer river model of kidney cancer.
    Hsieh JJ; Manley BJ; Khan N; Gao J; Carlo MI; Cheng EH
    Semin Cell Dev Biol; 2017 Apr; 64():98-106. PubMed ID: 27615548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal cell carcinoma and proteomics.
    Sandim V; Pereira DA; Ornellas AA; Alves G
    Urol Int; 2010; 84(4):373-7. PubMed ID: 20224258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumoural heterogeneity may hinder precision medicine strategies in patients with clear cell renal cell carcinoma.
    Raspollini MR; Montagnani I; Montironi R; Castiglione F; Martignoni G; Cheng L; Lopez-Beltran A
    J Clin Pathol; 2018 May; 71(5):467-471. PubMed ID: 29317515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.
    Ghosh AP; Marshall CB; Coric T; Shim EH; Kirkman R; Ballestas ME; Ikura M; Bjornsti MA; Sudarshan S
    Oncotarget; 2015 Jul; 6(20):17895-910. PubMed ID: 26255626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Coordinated Actions of TIM-3 on Cancer and Myeloid Cells in the Regulation of Tumorigenicity and Clinical Prognosis in Clear Cell Renal Cell Carcinomas.
    Komohara Y; Morita T; Annan DA; Horlad H; Ohnishi K; Yamada S; Nakayama T; Kitada S; Suzu S; Kinoshita I; Dosaka-Akita H; Akashi K; Takeya M; Jinushi M
    Cancer Immunol Res; 2015 Sep; 3(9):999-1007. PubMed ID: 25783986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer.
    Cho D; Signoretti S; Regan M; Mier JW; Atkins MB
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):758s-763s. PubMed ID: 17255306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine.
    Audenet F; Yates DR; Cancel-Tassin G; Cussenot O; Rouprêt M
    BJU Int; 2012 Jun; 109(12):1864-70. PubMed ID: 22035299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolomics in renal cell carcinoma: From biomarker identification to pathomechanism insights.
    Chen YY; Hu HH; Wang YN; Liu JR; Liu HJ; Liu JL; Zhao YY
    Arch Biochem Biophys; 2020 Nov; 695():108623. PubMed ID: 33039388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenging the treatment paradigm for advanced renal cell carcinoma: a review of systemic and localized therapies.
    Bex A; Larkin J; Voss M
    Am Soc Clin Oncol Educ Book; 2015; ():e239-47. PubMed ID: 25993179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic reprogramming in clear cell renal cell carcinoma.
    Wettersten HI; Aboud OA; Lara PN; Weiss RH
    Nat Rev Nephrol; 2017 Jul; 13(7):410-419. PubMed ID: 28480903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib.
    Desar IM; Stillebroer AB; Oosterwijk E; Leenders WP; van Herpen CM; van der Graaf WT; Boerman OC; Mulders PF; Oyen WJ
    J Nucl Med; 2010 Nov; 51(11):1707-15. PubMed ID: 20956472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular biology of renal cell cancer and the identification of therapeutic targets.
    Iliopoulos O
    J Clin Oncol; 2006 Dec; 24(35):5593-600. PubMed ID: 17158545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour necrosis factor receptor-associated factor-1 (TRAF-1) expression is increased in renal cell carcinoma patient serum but decreased in cancer tissue compared with normal: potential biomarker significance.
    Rajandram R; Yap NY; Pailoor J; Razack AH; Ng KL; Ong TA; Morais C; Gobe GC
    Pathology; 2014 Oct; 46(6):518-22. PubMed ID: 25158810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy.
    Stillebroer AB; Mulders PF; Boerman OC; Oyen WJ; Oosterwijk E
    Eur Urol; 2010 Jul; 58(1):75-83. PubMed ID: 20359812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and future strategies in nonclear-cell metastatic renal cell carcinoma.
    Albiges L; Escudier B
    Curr Opin Urol; 2015 Sep; 25(5):367-73. PubMed ID: 26153638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel immunotherapeutic strategies in development for renal cell carcinoma.
    Inman BA; Harrison MR; George DJ
    Eur Urol; 2013 May; 63(5):881-9. PubMed ID: 23084331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of FABP7 promotes cell growth and predicts poor prognosis of clear cell renal cell carcinoma.
    Zhou J; Deng Z; Chen Y; Gao Y; Wu D; Zhu G; Li L; Song W; Wang X; Wu K; He D
    Urol Oncol; 2015 Mar; 33(3):113.e9-17. PubMed ID: 25192834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular cell adhesion molecule 1 predicts cancer-free survival in clear cell renal carcinoma patients.
    Shioi K; Komiya A; Hattori K; Huang Y; Sano F; Murakami T; Nakaigawa N; Kishida T; Kubota Y; Nagashima Y; Yao M
    Clin Cancer Res; 2006 Dec; 12(24):7339-46. PubMed ID: 17189405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.